BioCryst Pharmaceuticals Company Profile (NASDAQ:BCRX)

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. Its drug candidates include RAPIVAB, RAPIACTA, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, BCX4430 and Forodesine. Its product RAPIVAB contains peramivir. Peramivir is an intravenous neuraminidase inhibitor approved in various countries for the treatment of patients with influenza, in the United States as RAPIVAB. RAPIVAB is used for the treatment of acute uncomplicated influenza. Its BCX4430 is a broad-spectrum antiviral (BSAV) research program.

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology
Sub-Industry: Biotechnology
Exchange: NASDAQ
Symbol: BCRX
CUSIP: 09058V10

Key Metrics:

Previous Close: $4.42
50 Day Moving Average: $4.462
200 Day Moving Average: $3.465
52-Week Range: $1.63 - $12.88
Trailing P/E Ratio: N/A
Foreward P/E Ratio: -4.64
P/E Growth: -0.230
Market Cap: $325.39M
Outstanding Shares: 73,700,000
Beta: 3.19

Profitability:

Net Margins: -285.24%
Return on Equity: -187.98%
Return on Assets: -64.08%

Debt:

Debt-to-Equity Ratio: 0.19%
Current Ratio: 0.82%
Quick Ratio: 0.79%

Additional Links:

Companies Related to BioCryst Pharmaceuticals:

Consensus Ratings for BioCryst Pharmaceuticals (NASDAQ:BCRX) (?)

Ratings Breakdown:	1 Sell Rating, 5 Hold Ratings, 5 Buy Ratings
Consensus Rating:	Hold (Score: 2.36)
Consensus Price Target:	$8.22 (86.44% upside)

Analysts' Ratings History for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Show:

Date	Firm	Action	Rating	Price Target
9/8/2016	FBR & Co	Reiterated Rating	Buy
8/12/2016	Piper Jaffray Cos.	Upgrade	Neutral -> Overweight	$5.00 -> $8.00
8/5/2016	HC Wainwright	Reiterated Rating	Buy
8/5/2016	JPMorgan Chase & Co.	Reiterated Rating	Hold
8/5/2016	Jefferies Group	Boost Price Target	Hold	$2.00 -> $3.00
8/4/2016	JMP Securities	Downgrade	Outperform -> Market Perform
2/26/2016	Noble Financial	Reiterated Rating	Buy	$8.00
2/9/2016	Rodman & Renshaw	Lower Price Target	Buy	$24.00 -> $10.00
2/8/2016	Needham & Company LLC	Downgrade	Buy -> Hold
11/11/2015	Bank of America Corp.	Downgrade	Neutral -> Underperform	$12.00 -> $10.00
11/10/2015	Oppenheimer Holdings Inc.	Reiterated Rating	Market Perform
8/10/2015	MLV & Co.	Reiterated Rating	Buy	$15.00

(Data available from 9/30/2014 forward)

Earnings History for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/7/2016
8/4/2016	Q216	($0.26)	($0.22)	$3.92 million	$4.80 million	View	N/A
5/5/2016	Q116	($0.23)	($0.31)	$5.42 million	$4.82 million	View	N/A
2/23/2016	Q415	($0.26)	($0.25)	$6.34 million	$4.60 million	View	Listen
11/5/2015	Q315	($0.20)	($0.20)	$6.77 million	$11.00 million	View	Listen
8/7/2015	Q215	($0.22)	$0.06	$7.10 million	$25.80 million	View	Listen
5/8/2015	Q115	($0.24)	($0.21)	$4.30 million	$6.80 million	View	Listen
2/18/2015	Q414	($0.21)	($0.16)	$3.64 million	$5.40 million	View	Listen
11/6/2014	Q314	($0.20)	($0.12)	$2.11 million	$3.20 million	View	Listen
8/5/2014	Q214	($0.19)	($0.23)	$2.32 million	$1.50 million	View	N/A
5/8/2014	Q114	($0.17)	($0.17)	$3.34 million	$3.50 million	View	N/A
2/26/2014	Q413	($0.08)	($0.09)	$8.81 million	$10.60 million	View	N/A
11/5/2013	Q313	($0.14)	($0.14)	$2.01 million	$2.40 million	View	N/A
8/8/2013	Q2 2013	($0.14)	($0.23)	$2.01 million	$0.82 million	View	N/A
5/7/2013	Q1 2013	($0.15)	($0.09)	$1.31 million	$3.60 million	View	N/A
2/19/2013	Q4 2012	($0.16)	($0.22)	$4.02 million	$4.10 million	View	N/A
11/8/2012	Q312	($0.22)	($0.19)	$4.63 million	$5.80 million	View	N/A
8/2/2012		($0.26)	($0.25)			View	N/A
5/7/2012		($0.26)	($0.13)			View	N/A
2/16/2012		($0.33)	($0.29)			View	N/A
11/2/2011		($0.30)	($0.32)			View	N/A
8/4/2011		($0.26)	($0.36)			View	N/A
5/4/2011		($0.20)	($0.29)			View	N/A
2/10/2011		($0.21)	($0.20)			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Current Year EPS Consensus Estimate: $-1.03 EPS
Next Year EPS Consensus Estimate: $-0.95 EPS

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2016	4	($0.24)	($0.20)	($0.23)
Q2 2016	5	($0.25)	($0.17)	($0.22)
Q3 2016	3	($0.26)	($0.22)	($0.24)
Q4 2016	3	($0.26)	($0.24)	($0.25)

(Data provided by Zacks Investment Research)

Dividend History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Insider Ownership Percentage: 5.80%
Institutional Ownership Percentage: 70.34%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
9/14/2016	Alane P Barnes	VP	Sell	8,357	$4.27	$35,684.39
8/25/2016	Yarlagadda S Babu	VP	Sell	30,000	$4.06	$121,800.00
8/16/2016	Bros. Advisors Lp Baker	Major Shareholder	Sell	4,046,590	$5.00	$20,232,950.00
8/12/2016	Thomas R Staab II	Insider	Sell	5,864	$5.18	$30,375.52
8/9/2016	Thomas R Staab II	Insider	Sell	14,577	$4.43	$64,576.11
1/28/2016	Bros. Advisors Lp Baker	major shareholder	Buy	88,345	$6.95	$613,997.75
1/22/2016	Bros. Advisors Lp Baker	major shareholder	Buy	106,800	$7.28	$777,504.00
1/20/2016	Bros. Advisors Lp Baker	major shareholder	Buy	52,695	$6.87	$362,014.65
1/19/2016	Bros. Advisors Lp Baker	major shareholder	Buy	92,200	$7.12	$656,464.00
1/15/2016	Bros. Advisors Lp Baker	major shareholder	Buy	200,000	$7.46	$1,492,000.00
12/21/2015	Thomas R Staab II	CFO	Sell	3,052	$10.86	$33,144.72
12/17/2015	Thomas R Staab II	CFO	Sell	3,000	$10.49	$31,470.00
7/20/2015	Thomas R Staab II	CFO	Sell	3,500	$16.50	$57,750.00
6/22/2015	Thomas R Staab II	CFO	Sell	3,750	$16.00	$60,000.00
6/19/2015	Alane P Barnes	VP	Sell	3,000	$15.00	$45,000.00
6/19/2015	Jon P Stonehouse	CEO	Sell	20,000	$15.02	$300,400.00
6/19/2015	Thomas R Staab II	CFO	Sell	16,375	$14.36	$235,145.00
6/19/2015	William P Sheridan	CMO	Sell	70,389	$15.05	$1,059,354.45
6/5/2015	Thomas R Staab II	CFO	Sell	6,000	$12.75	$76,500.00
5/18/2015	Thomas R Staab II	CFO	Sell	3,000	$11.00	$33,000.00
3/19/2015	Yarlagadda S Babu	VP	Sell	12,105	$10.16	$122,986.80
3/5/2015	Yarlagadda S Babu	VP	Sell	37,400	$10.59	$396,066.00
3/4/2015	Yarlagadda S Babu	VP	Sell	10,495	$10.50	$110,197.50
2/20/2015	Nancy J Hutson	Director	Buy	10,000	$10.27	$102,700.00
12/30/2014	William P Sheridan	CMO	Sell	128,399	$12.36	$1,587,011.64
12/29/2014	Thomas R Staab II	CFO	Sell	9,500	$12.56	$119,320.00
12/29/2014	William P Sheridan	CMO	Sell	105,295	$12.43	$1,308,816.85
8/27/2014	Thomas R Staab II	CFO	Sell	10,000	$13.58	$135,800.00
7/1/2014	Thomas R Staab II	CFO	Sell	3,125	$13.00	$40,625.00
6/23/2014	Thomas R Staab II	CFO	Sell	3,125	$12.49	$39,031.25
6/17/2014	Thomas R Staab II	CFO	Sell	3,125	$12.00	$37,500.00
3/14/2014	Thomas Staab II	CFO	Sell	3,125	$11.24	$35,125.00
3/6/2014	Kenneth Lee, Jr.	Director	Sell	12,665	$12.69	$160,718.85
11/12/2013	George Abercrombie	Director	Buy	3,000	$6.19	$18,570.00
8/1/2013	Felix Baker	Major Shareholder	Buy	1,136,364	$4.40	$5,000,001.60
3/5/2013	George B Abercrombie	Director	Buy	3,000	$1.23	$3,690.00
12/14/2012	Peder Jensen	Director	Buy	20,000	$1.51	$30,200.00

(Data available from 1/1/2013 forward)

Latest Headlines for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Date	Headline
	Latest Analyst Ratings For BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - The De Soto Edge (NASDAQ:BCRX) desotoedge.com - September 29 at 4:00 PM
	BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Is Expected To Post EPS Of $-0.22 - RealistInvestor.com (NASDAQ:BCRX) www.realistinvestor.com - September 29 at 4:00 PM
	BioCryst Closes $23 Million Senior Credit Facility (NASDAQ:BCRX) www.publicnow.com - September 29 at 8:52 AM
	BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fin (NASDAQ:BCRX) biz.yahoo.com - September 29 at 8:52 AM
	Biotech news that matter for investors: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Celldex Therapeutics, Inc ... - The Voice Registrar (NASDAQ:BCRX) voiceregistrar.com - September 26 at 3:52 PM
	BioCryst Pharmaceuticals : Closes $23 Million Senior Credit Facility (NASDAQ:BCRX) www.4-traders.com - September 26 at 8:31 AM
	ETF’s with exposure to BioCryst Pharmaceuticals, Inc. : September 21, 2016 (NASDAQ:BCRX) www.capitalcube.com - September 21 at 4:40 PM
	News review of 2 biotech stocks: BioCryst Pharmaceuticals (NASDAQ:BCRX), Vanda Pharmaceuticals (NASDAQ:VNDA) - The Voice Registrar (NASDAQ:BCRX) voiceregistrar.com - September 20 at 5:55 PM
	Biotech Stocks Worth a Closer Look: Sangamo Biosciences Inc. (NASDAQ:SGMO), BioCryst Pharmaceuticals, Inc ... - The Voice Registrar (NASDAQ:BCRX) voiceregistrar.com - September 20 at 5:55 PM
	Quarterly EPS analysis of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Newburgh Press (NASDAQ:BCRX) newburghpress.com - September 20 at 5:55 PM
	What are Brokerage Firms Saying About BioCryst Pharmaceuticals ... - Frisco Fastball (NASDAQ:BCRX) friscofastball.com - September 17 at 3:46 PM
	Stock Perspective: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Earnings in View - Frisco Fastball (NASDAQ:BCRX) friscofastball.com - September 15 at 4:18 PM
	Time To Put On The Watch List? - BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Sangamo Biosciences Inc ... - The Voice Registrar (NASDAQ:BCRX) voiceregistrar.com - September 15 at 4:18 PM
	Healthcare Shares Need To Consider: BioCryst Pharmaceuticals ... - National Daily Press (NASDAQ:BCRX) www.nationaldailypress.com - September 14 at 3:48 PM
	Time To Put On The Watch List? - BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Inovio Pharmaceuticals, Inc ... - The Voice Registrar (NASDAQ:BCRX) voiceregistrar.com - September 13 at 4:47 PM
	Time To Put On The Watch List? - BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Rock Creek Pharmaceuticals, Inc ... - The Voice Registrar (NASDAQ:BCRX) voiceregistrar.com - September 9 at 3:43 PM
	BioCryst Pharma (BCRX) Offers Positive Results from BCX4430 PoC Study in Ebola Virus - StreetInsider.com (NASDAQ:BCRX) www.streetinsider.com - September 9 at 8:38 AM
	BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) From The Analysts Point of View - National Daily Press (NASDAQ:BCRX) www.nationaldailypress.com - September 9 at 8:38 AM
	Active Eye Catching Stocks- BioCryst Pharmaceuticals (BCRX), Retrophin (RTRX), Immune Pharmaceuticals (IMNP) - Seneca Globe (NASDAQ:BCRX) www.senecaglobe.com - September 8 at 8:54 AM
	Stock Showing Gains in Today's Session: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Post News (NASDAQ:BCRX) www.kentuckypostnews.com - September 7 at 3:45 PM
	BioCryst Announces Positive Study Results for BCX4430 Delayed Treatment of Ebola Virus Infection in a Non-Human Primate Model (NASDAQ:BCRX) www.publicnow.com - September 7 at 11:01 AM
	BioCryst to Present at the Baird 2016 Global Healthcare Conference September 8 (NASDAQ:BCRX) finance.yahoo.com - August 31 at 3:46 PM
	BioCryst Pharmaceuticals Inc (NASDAQ:BCRX): A Play On The Zika Virus (NASDAQ:BCRX) streetregister.com - August 30 at 9:10 AM
	ETF’s with exposure to BioCryst Pharmaceuticals, Inc. : August 29, 2016 (NASDAQ:BCRX) www.capitalcube.com - August 29 at 4:21 PM
	Research Reports Initiation on Biotech Stocks -- Hemispherx Biopharma, Vascular Biogenics, BioCryst Pharma, and Alnylam Pharma (NASDAQ:BCRX) www.prnewswire.com - August 29 at 8:34 AM
	After Yesterday's Decline of 5.13%, BioCryst Pharmaceuticals Offers Investors Better Value (NASDAQ:BCRX) www.mysmartrend.com - August 25 at 9:10 PM
	Biotech news that matter for investors: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Arrowhead Pharmaceuticals ... - The Voice Registrar (NASDAQ:BCRX) voiceregistrar.com - August 24 at 12:00 PM
	Biocryst Pharmaceuticals Inc (BCRX): Billionaire David E. Shaw’s Fund Increases Stake (NASDAQ:BCRX) www.insidermonkey.com - August 23 at 3:50 PM
	BIOCRYST PHARMACEUTICALS INC Financials (NASDAQ:BCRX) finance.yahoo.com - August 17 at 3:52 PM
	Biocryst Pharmaceuticals Inc (BCRX): Baker Bros. Advisors Unloads Nearly 4 Million Shares (NASDAQ:BCRX) www.insidermonkey.com - August 17 at 11:57 AM
	2 Biotech Stocks News And Price Trends: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), ZIOPHARM Oncology, Inc ... - The Voice Registrar (NASDAQ:BCRX) voiceregistrar.com - August 16 at 3:51 PM
	Will BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Hit $10 Price Target? - Investor Newswire (NASDAQ:BCRX) www.investornewswire.com - August 16 at 12:28 PM
	Stocks to Watch: BioCryst Pharmaceuticals, Inc.(NASDAQ:BCRX), First Solar, Inc.(NASDAQ:FSLR) - NYSE Journal (press release) (NASDAQ:BCRX) stockznews.com - August 15 at 3:53 PM
	ETF’s with exposure to BioCryst Pharmaceuticals, Inc. : August 15, 2016 (NASDAQ:BCRX) www.capitalcube.com - August 15 at 11:00 AM
	BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Brokerage Rating Update - Investor Newswire (NASDAQ:BCRX) www.investornewswire.com - August 12 at 3:58 PM
	BioCryst Pharmaceuticals, Inc. :BCRX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 (NASDAQ:BCRX) www.capitalcube.com - August 12 at 3:58 PM
	BioCryst Pharma (BCRX) Does First Patient in BCX7353 APeX-1 Study (NASDAQ:BCRX) www.streetinsider.com - August 12 at 12:25 PM
	BioCryst Pharma upgraded by Piper Jaffray (NASDAQ:BCRX) finance.yahoo.com - August 12 at 12:25 PM
	Analyst's keeping an Eye on: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Post Registrar (NASDAQ:BCRX) postregistrar.com - August 11 at 9:40 PM
	10:19 am BioCryst Pharma doses the first subject in the APeX-1 clinical trial of BCX7353 for the oral treatment of hereditary angioedema (NASDAQ:BCRX) finance.yahoo.com - August 11 at 12:32 PM
	BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:BCRX) biz.yahoo.com - August 11 at 12:32 PM
	BioCryst Announces Initiation of the APeX-1 Clinical Trial of BCX7353 for Hereditary Angioedema (NASDAQ:BCRX) www.publicnow.com - August 11 at 12:32 PM
	Here's the Buzz Behind BioCryst Pharmaceuticals, Inc.'s 27% Gain in July (NASDAQ:BCRX) www.fool.com - August 11 at 12:32 PM
	Bulls pile into Biocryst Pharmaceuticals (NASDAQ:BCRX) finance.yahoo.com - August 10 at 4:11 PM
	Biocryst Where To From Here? - Seeking Alpha (NASDAQ:BCRX) seekingalpha.com - August 10 at 7:52 AM
	Stocks inside Analysts Limelight: Amarin Corporation PLC (NASDAQ:AMRN) , BioCryst Pharmaceuticals, Inc ... - Street Updates (NASDAQ:BCRX) www.streetupdates.com - August 10 at 7:52 AM
	Biggest Movers in Healthcare: MannKind Corp. (NASDAQ:MNKD), BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - TWN (NASDAQ:BCRX) thewellesleysnews.com - August 10 at 7:52 AM
	BIOCRYST PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report (NASDAQ:BCRX) biz.yahoo.com - August 8 at 3:49 PM
	Edited Transcript of BCRX earnings conference call or presentation 4-Aug-16 3:00pm GMT (NASDAQ:BCRX) finance.yahoo.com - August 5 at 9:09 PM
	Notable Stock Analyst Ratings: Primoris Services Corp (NASDAQ:PRIM), BioCryst Pharmaceuticals, Inc. (NASDAQ ... - Review Fortune (NASDAQ:BCRX) reviewfortune.com - August 5 at 3:47 PM